Long-term maintenance therapy of depressive disorders with antidepressants: experience of using agomelatin

Tyuvina N.A.; Stolyarova A.E.; Chudova A.B.

doi:https://doi.org/10.17116/jnevro202112106187

Tyuvina N.A.

Sechenov First Moscow State Medical University (Sechenov University)

Stolyarova A.E.

Sechenov First Moscow State Medical University (Sechenov University)

Chudova A.B.

Sechenov First Moscow State Medical University (Sechenov University)

Long-term maintenance therapy of depressive disorders with antidepressants: experience of using agomelatin

Authors:

Tyuvina N.A., Stolyarova A.E., Chudova A.B.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(6): 87‑92

DOI: 10.17116/jnevro202112106187

Read: 5656 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Tyuvina NA, Stolyarova AE, Chudova AB. Long-term maintenance therapy of depressive disorders with antidepressants: experience of using agomelatin. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(6):87‑92. (In Russ.)
https://doi.org/10.17116/jnevro202112106187

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Pathogenetic interrelations of hypogonadism and depression in men. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):17-23

Nutritional care for patients with neurodegenerative diseases in the outpatient practice of a neurologist. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):76-83

Clinical and immunological relationships in patients with early schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):35-42

A personalized approach to the treatment of chronic tension headache and comorbid mental disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):51-57

Asthenia in the acute period of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):5-10

The state of mental health of migrant workers and citizens of the Russian Federation: A comparative analysis as illustrated by the Moscow region. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):95-101

Factors of depression according to actigraphy in the fall season. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):27-32

Identification of depression biomarkers: Prospects for use in clinical practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):51-55

Depression Anxiety Stress Scale (russian language version). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):103-107

Experience with the use of amitriptyline for chronic pelvic pain associated with endometriosis. Russian Journal of Human Reproduction. 2025;(1):86-93

Abstract:

The article presents the literature data that determine the place of antidepressants in the relief and maintenance therapy for recurrent depression (RD) and depression in the framework of bipolar affective disorder (BPAD) and provides a justification for their use in the presence of residual depressive symptoms during remission. There are several ways to achieve complete remission: determination of the nature of residual symptoms; identification of adverse side-effects that have occurred as a result of the therapy; the establishment of those symptoms that are subjectively perceived by the patient as interfering with his/her full life. The data on the effective use of agomelatin for maintenance therapy, both as monotherapy and in combination with other antidepressants, anticonvulsants and neuroleptics, in RD and BPAD are presented. The authors have analyzed the case histories of 29 outpatients with depressions of various origins (RDD, BPAD, prolonged psychogenic depression, organic affective disorder), who received agomelatin as part of complex and monotherapy for a long time (1 to 13 years), and justified the predictors of its efficacy.

Keywords:

agomelatin

depression

supportive care

residual symptoms

remission

Authors:

Tyuvina N.A.

Sechenov First Moscow State Medical University (Sechenov University)

Stolyarova A.E.

Sechenov First Moscow State Medical University (Sechenov University)

Chudova A.B.

Sechenov First Moscow State Medical University (Sechenov University)

Received:

13.05.2021

Accepted:

29.06.2021

Close metadata

References:

Tyuvina NA, Smirnova VN. A comparative evaluation of the efficacy of valdoxan (agomelatine) in recurrent depression and bipolar affective disorder. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2012;11:53-60. (In Russ.).
Goodwin G.M. Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2009;23(4):346-388. https://doi.org/10.1177/0269881109102919
American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision) Am J Psychiatry. 2002;159(suppl 4):1-50.
Frances AJ, Docherty JP, Kahn DA The expert consensus guideline series: treatment of bipolar disorder. J Clin Psychiatry. 1996;57:1-88.
Frances AJ, Kahn DA, Carpenter D, Docherty JP, Donovan SL. The Expert Consensus Guidelines for treating depression in bipolar disorder. J Clin Psychiatry. 1998;59(suppl 4):73-79.
Yathem L, Kennedy SH, OXDonovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Dis. 2009;11:225-255. https://doi.org/10.1111/j.1399-5618.2009.00672.x
Eppel AB. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord. 2008;10(6):749-750; author reply 750-751. https://doi.org/10.1111/j.1399-5618.2008.00586.x
Prien RF, Klett CJ, Caffey EM. Lithium carbonate and imipramine in the prevention of affective episodes. Arch Gen Psychiatry. 1973;29:420-425. https://doi.org/10.1001/archpsyc.1973.04200030104017
Kostyukova EG. Questions of therapy and diagnosis and therapy of depression within various nosological categories. Sovremennaya terapiya psihicheskih rasstrojstv. 2017;2:44-56. (In Russ.).
Mosolov SN, Ushkalova AV, Kostyukova EG. Diagnosis of type II bipolar affective disorder among patients with a current diagnosis of recurrent depressive disorder. Sovremennaya terapiya psihicheskih rasstrojstv. 2014;2:2-12. (In Russ.).
Baldessarini RJ, Vázquez GH, Tondo L. Bipolar depression: a major unsolved challenge. Int J Bipolar Disord. 2020;8(1):1. https://doi.org/10.1186/s40345-019-0160-1
Tyuvina NA, Smirnova VN. Bipolar affective disorders: the specific features of the course and maintenance pharmacotherapy. Nevrologiya, Neiropsikhiatriya, Psikhosomatika. 2013;5(1):87-95. (In Russ.). https://doi.org/10.14412/2074-2711-2013-2406
Judd LL, Akiskal HS, Schlettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60:261-269. https://doi.org/10.1001/archpsyc.60.3.261
Judd LL, Akiskal HS, Schlettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59:530. https://doi.org/10.1001/archpsyc.59.6.530
Joffe RT, MacQueen GM, Marriott M, et al. A prospective, longitudinal study of percentage of time spent ill in patients with bipolar 1 or bipolar 2 disorders. Bipolar Dis. 2004;6:62-66. https://doi.org/10.1046/j.1399-5618.2003.00091.x
Petrova NN. Clinical and functional assessment of remission in patients with recurrent depression. Nevrologiya, nejropsihiatriya, psihosomatika. 2019;11(4):88-93. (In Russ.). https://doi.org/10.14412/2074-2711-2019-4-88-93
Zimmerman M, McGlinchey JB, Posternak MA, et al. How should remission from depression be defined? The depressed patient’s perspective. Am J Psychiatry. 2006;163(1):148-150. https://doi.org/10.1176/appi.ajp.163.1.148
Demyttenaere K, Donneau AF, Albert A, et al. What is important in being cured from depression. Discordance between physicians and patients. J Affect Disord. 2015;174:390-396. https://doi.org/10.1016/j.jad.2014.12.004
Bekker RA, Bykov YuV. Apathy syndrome in depressive patients treated with selective serotonin reuptake inhibitors. Anhedonia in psychiatry and modern possibilities of its psychopharmacological correction with the help of the drug Valdoxan (agomelatin). Psihiatriya i psihofarmakoterapiya. 2019;21(5):22-29. (In Russ.).
Sajatovic M, Valenstein M, Blow FC, et al. Treatment adherence with antipsychotic med- ications in bipolar disorder. Bipolar Dis. 2006;8:231-232. https://doi.org/10.1111/j.1399-5618.2006.00314.x
Barnhart WJ, Makela EH, Lotocha MJ. SSRI-induced apathy syndrome: a clinical review. J Psychiatr Pract. 2004;10(3):196-199. https://doi.org/10.1097/00131746-200405000-00010
Garland EJ, Baerg EA. Amotivational syn- drome associated with selective serotonin reuptake inhibitors in children and adolescents. J Child Adolesc Psychopharmacol. 2001;11(2):181-186. https://doi.org/10.1089/104454601750284090
Price J, Cole V, Goodwin GM. Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study. Br J Psychiatry. 2009;195(3):211-217. https://doi.org/10.1192/bjp.bp.108.051110
Medvedev VE, Kardashyan RA, Frolova VI, Burno AM, Nekrasova SV, Salyncev IV. To study the effectiveness of various antidepressant replacement regimens in the development of SSRI-induced apathy. Nevrologiya, nejropsihiatriya, psihosomatika. 2020;12(2):48-56. (In Russ.). https://doi.org/10.14412/2074-2711-2020-2-48-56
Petrova NN, Markin AV. Apathy syndrome in depressive patients treated with selective serotonin reuptake inhibitors. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2020;120(1):111-117. (In Russ.). https://doi.org/10.17116/jnevro2020120011111
Bolling MY, Kohlenberg RJ. Reasons for quitting serotonin reuptake inhibitor therapy: paradoxical psychological side effects and patients satisfaction. Psychother Psychosom. 2004;73(6):380-385. https://doi.org/10.1159/000080392
Price J, Goodwin G. Emotional blunting or reduced reactivity following remission of major depression. Medicographia. 2009;31:152-156.
Sato S. Reconsidering the term ‘disinhibition’ in selective serotonin reuptake inhibitorsinduced apathy syndrome. Psychiatry Clin Neurosci. 2018;72(8):624. https://doi.org/10.1111/pcn.12678
McCabe C, Mishor Z, Cowen PJ, Harmer CJ. Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biol Psychiatry. 2010;67(5):439-445. https://doi.org/10.1016/j.biopsych.2009.11.001
Briley M. Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors. Neuropsychiatr Dis Treat. 2010;6:647-655. https://doi.org/10.2147/NDT.S13171
Mazo GE, Neznanov NG. Therapeutically resistant depressions. SPb. 2012. (In Russ.).
Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge University Press. 2013;626.
Di Giannantonio M, Di Iorio G, Guglielmo R, et al. Major depressive disorder, anhedonia and agomelatine: an open-label study. J Biol Regul Homeost Agents. 2011;25(1):109-114.
Llorca PM, Gourion P. P.2.f.028. Course of anhedonia and depressive symptoms in a popu- lation of depressed outpatients treated with agomelatine. Eur Neuropsychopharmacol. 2014;24(suppl 2):468. https://doi.org/10.1016/s0924-977x(14)70749-7
Gorwood P, Benichou J, Rouillon F, Wattez M. Efficacy and safety of agomelatine over one year. A French prospective observational study of depressed patients followed-up in medical practice. European Neuropsychopharmacology. 2016;26(suppl 2):456-457. https://doi.org/10.1016/S0924-977X(16)31448-1
Vorob’eva OV. Valdoxan in depression therapy in neurological practice: results of the Russian multicenter naturalistic study «Resonance». Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2012;112(9):47-51. (In Russ.).
Chernova EV, Kozhechkina OV, Ter-Israelyan AYu, Medvedev VE. Therapy with agomelatin (valdoxan) for endogenous depression in a day hospital. Zhurnal nevrologii i psikhiatriiim. S.S. Korsakova. 2016;116(10):43-46. (In Russ.). https://doi.org/10.17116/jnevro201611610143-46
Tyuvina NA, Stolyarova AE, Smirnova VN. Bipolar affective disorder: gender characteristics of the course and therapy. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2019;119(12):162-169. (In Russ.). https://doi.org/10.17116/jnevro2019119121162
Medvedev VE. The use of valdoxan (agomelatin) in the combined therapy of moderate to severe depression of non-psychotic level. ZHurnal nevrologii i psihiatrii im. S.S. Korsakova. 2012;112:5:1:37-40. (In Russ.).
Medvedev VE. The possibility of combined therapy of depression with melatonergic and tricyclic antidepressants. Psihiatriya i psihofarmakoterapiya im. P.B. Gannushkina. 2012;1:53-56. (In Russ.)
Medvedev VE. Combination therapy of depression with valdoxan (agomelatin) and antipsychotics. Psihiatriya i psihofarmakoterapiya im. P.B. Gannushkina. 2012;2:20-23. (In Russ.).